3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
26
Phase 1
4
Phase 1/2
3
Phase EARLY_PHASE1
2
Phase 4
2
Phase 3
2
Phase NA
1
Phase 2/3
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
5
Other
4
Breast
4
CNS
3
Head & Neck
2
Gynecologic
2
Genitourinary
2
Thoracic
1
Conditions
Prostatic Neoplasms
2
Neoplasms
1
Metabolic Syndrome
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
66
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
43
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
31
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Nivolumab
24
Triptorelin Pamoate
23
Sunitinib
23
apalutamide
22
Radiation
22
Doxorubicin
20
darolutamide
19
abiraterone
18
Gonadotropin-Releasing Hormone
18
cabozantinib
17
atezolizumab
16
Specimen Handling
16
Radiosurgery
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Metformin
×
Genitourinary
×
Clear all
NCT03031821
2024-10-04
PRIME
Canadian Urologic Oncology Group
Phase 3
Terminated
168 enrolled
NCT01864096
2024-01-24
MAST
University Health Network, Toronto
Phase 3
Unknown
408 enrolled